[1]Patent:WO2007/84786,2007,A1.Locationinpatent:Page/Pagecolumn139-140;164
[2]JournalofMedicinalChemistry,2016,vol.59,p.7268-7274
[3]Patent:WO2012/109423,2012,A1.Locationinpatent:Page/Pagecolumn29
[1]Patent:WO2012/44727,2012,A2.Locationinpatent:Page/Pagecolumn66-67
[2]Patent:CN105461714,2016,A.Locationinpatent:Paragraph0242;0243;0253;0254;0255
[3]Patent:CN105541792,2016,A.Locationinpatent:Paragraph0235;0236;0237
[1]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2012/44727,2012,A2Locationinpatent:Page/Pagecolumn73-74
[1]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2014/64058,2014,A1Locationinpatent:Page/Pagecolumn28;29
Title: Burger MT, et al. Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett. 2011 Aug 26;2(10):774-9.
Title: Zheng Y, et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity. J Mol Med (Berl). 2012 Jun;90(6):695-706.
Title: Ni J, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 Jul;22(7):723-6.
Title: Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369.
